Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Morphologic evidence of acute myeloid leukemia in first relapse.~2. Phase I: 18 years or older, Phase II: 50 years or older~Exclusion Criteria:~1. Prior treatment with zosuquidar~2. Any investigational agent within 1 month of enrollment and lack of recovery from toxicities secondary to those agents~3. History of stem cell transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).